| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 50,871 | 13,339 |
| Net increase in cash, cash equivalents and restricted cash | 7,466 | -11,279 |
| Cash and cash equivalents at beginning of period | 29,854 | - |
| Cash and cash equivalents at end of period | 37,320 | - |
BioXcel Therapeutics, Inc. (BTAI)
BioXcel Therapeutics, Inc. (BTAI)